PsymaTalk: Our Take on ASCO 2018 - Part 1
with Gordon Gochenauer, Oncology lead at Psyma USA
Gordon Gochenauer, shares his takeaways from ASCO 2018 in a podcast miniseries.
In this Part 1, Array Biopharma’s RAF/MEK combination, encorafenib and binimetinib, nicknamed COMBO450, posted a median overall survival of 33 months in BRAF-mutated melanoma in the COLUMBUS trial. This new combination, likely to be approved by the end of June 2018, may be well-positioned to challenge Genentech/Roche’s and Novartis’ respective RAF/MEK combinations which have not surpassed 30 months in OS in trials.
Contact us to find out more about our Oncology Practice.